ACE2 and COVID-19: ACE2 inhibition was reported as being unfavorable in COVID-19 patients due to the consequent decrease in the production of angiotensin 1–7, that possess anti-inflammatory, antifibrotic and vasodilatory actions via the Mas receptor [31].